Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Mikrochim Acta ; 190(4): 137, 2023 03 15.
Artigo em Inglês | MEDLINE | ID: mdl-36920658

RESUMO

A conventional colorimetric method based on CuS-catalyzed H2O2 is improved by a dual-modification strategy and employed for thioglycolic acid (TGA) determination. The doping of Co(II) can enhance ion exchange efficiency. Meanwhile, the modification of g-C3N4 can increase specific surface area and decrease unspecific aggregation. The constructed g-C3N4/Co-CuS nanocomposite exhibited a favorable catalytic feature. A Michaelis constant (Km) value of 0.02 mM has been achieved, which is 1/160 of those of CuS and horseradish peroxidase (HRP). The g-C3N4/Co-CuS displays a rapid color response in 3 min and resulted in a stable measurable signal within 10 min. In the determination procedure, the sulfhydryl contained in TGA is capable of preventing TMB oxidation via competing the ·OH produced by catalysis and caused a color distinction that is related to the TGA amount. The distinctions of absorbance (λmax = 652 nm) of different concentrations of TGA are recorded. Linearity is obtained in the ranges of 2.5 - 20 µM and 20 - 160 µM, and the LOD is 0.14 µM. In the real sample assays of perm agent and Qianhu lake water, the recoveries were 96.70 - 106.84% and 100.21 - 101.90%, respectively. This demonstrates that the proposed dual-modification strategy for CuS contributes to highly efficient and convenient determination of TGA in daily cosmetics and water analysis.


Assuntos
Colorimetria , Peroxidase , Colorimetria/métodos , Peróxido de Hidrogênio/análise , Água
2.
Molecules ; 28(21)2023 Nov 06.
Artigo em Inglês | MEDLINE | ID: mdl-37959868

RESUMO

Radiation-induced skin injury (RISI) is a frequent and severe complication with a complex pathogenesis that often occurs during radiation therapy, nuclear incidents, and nuclear war, for which there is no effective treatment. Hyaluronan (HA) plays an overwhelming role in the skin, and it has been shown that UVB irradiation induces increased HA expression. Nevertheless, to the best of our knowledge, there has been no study regarding the biological correlation between RISI and HA degradation and its underlying mechanisms. Therefore, in our study, we investigated low-molecular-weight HA content using an enzyme-linked immunosorbent assay and changes in the expression of HA-related metabolic enzymes using real-time quantitative polymerase chain reaction and a Western blotting assay. The oxidative stress level of the RISI model was assessed using sodium dismutase, malondialdehyde, and reactive oxygen species assays. We demonstrated that low-molecular-weight HA content was significantly upregulated in skin tissues during the late phase of irradiation exposure in the RISI model and that HA-related metabolic enzymes, oxidative stress levels, the MEK5/ERK5 pathway, and inflammatory factors were consistent with changes in low-molecular-weight HA content. These findings prove that HA degradation is biologically relevant to RISI development and that the HA degradation mechanisms are related to HA-related metabolic enzymes, oxidative stress, and inflammatory factors. The MEK5/ERK5 pathway represents a potential mechanism of HA degradation. In conclusion, we aimed to investigate changes in HA content and preliminarily investigate the HA degradation mechanism in a RISI model under γ-ray irradiation, to consider HA as a new target for RISI and provide ideas for novel drug development.


Assuntos
Ácido Hialurônico , Pele , Ácido Hialurônico/farmacologia , Pele/metabolismo , Estresse Oxidativo , Espécies Reativas de Oxigênio/metabolismo , Oxirredução
3.
J Toxicol Sci ; 48(4): 179-189, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37005276

RESUMO

In this study, the toxicity effects on circulatory system and respiratory system, and the acute toxicity test of recombinant neorudin (EPR-hirudin, EH) in cynomolgus monkeys were evaluated to provide reference information for clinical studies. Eighteen cynomolgus monkeys were randomly divided into three groups for single intravenous administration of 3, 30 mg/kg EH and normal saline, respectively. The changes of respiratory frequency, respiratory intensity, blood pressure and electrocardiogram before and after administration were recorded. In acute toxicity test, six cynomolgus monkeys were intravenously received EH at a single dose of 171, 257, 385, 578, 867 and 1300 mg/kg respectively. The vital signs, hematology, serum biochemistry, coagulation indexes and electrocardiogram indexes of the animals were determined before administration and on the 7th and 14th day after administration. As the results showed that there were no significant abnormal changes in respiratory frequency, respiratory intensity, blood pressure or electrocardiogram in cynomolgus monkeys after receiving EH at 3 mg/kg and 30 mg/kg, and there was no statistical difference between the treated groups and normal saline group. In the acute toxicity test, no significant abnormalities were observed in vital signs, hematology, serum biochemistry, coagulation indexes and electrocardiogram indexes of six cynomolgus monkeys at day 7 and 14 after EH administration. Furthermore, autopsies of all cynomolgus monkeys showed no abnormalities. The results of toxicokinetics showed that AUClast of the drug increased in proportion to the EH dose in the range of 171-578 mg/kg, and increased in over proportion to the EH dose in the range of 578-1300 mg/kg. The variation of Cmax was basically consistent with AUClast. In a sum, A single intravenous injection of 3 and 30 mg/kg of EH did not affect the circulatory system and respiratory system in cynomolgus monkeys and the maximum tolerated dose of EH in cynomolgus monkey is over 1300 mg/kg (equivalent to 619-1300 times of the proposed clinical equivalent dose).


Assuntos
Sistema Cardiovascular , Hirudinas , Sistema Respiratório , Testes de Toxicidade Aguda , Animais , Sistema Cardiovascular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Hirudinas/administração & dosagem , Hirudinas/toxicidade , Infusões Intravenosas , Injeções Intravenosas , Macaca fascicularis , Sistema Respiratório/efeitos dos fármacos , Solução Salina/administração & dosagem
4.
Drug Des Devel Ther ; 17: 2523-2535, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37641688

RESUMO

Background: Whether anticoagulant therapy should be used after spinal-cord injury (SCI) surgery was controversial. The anticoagulation characteristics of a newly developed anticoagulant, recombinant neorudin (EPR-hirudin (EH)), were explored using a rat model of SCI to provide a basis for clinical anticoagulation therapy of SCI. Methods: A rat model of SCI was developed by Allen's method. Then, thrombosis in the inferior vena cava was induced by ligation. The low-bleeding characteristics of EH were explored by investigating dose-response and time-effect relationships, as well as multiple administration of EH, on thrombus formation complicated with SCI. Results: EH inhibited thrombosis in a dose-dependent manner by reducing the wet weight and dry weight of the thrombus. An inhibiting action of EH on thrombosis was most evident in the group given EH 2 h after SCI. After multiple intravenous doses of EH, thrombosis inhibition was improved to that observed with low molecular weight heparin (LMWH) (87% vs 90%). EH administration after SCI neither increased bleeding in the injured spine nor damaged to nerve function. Bleeding duration and activated partial thromboplastin time were increased in the high-dose EH group compared with that in the normal-saline group, but were lower than those in the LMWH group. Conclusion: EH can reduce thrombus formation in a rat model of SCI, and bleeding is decreased significantly compared with that using LMWH. EH may prevent thrombosis after SCI or spinal surgery.


Assuntos
Traumatismos da Medula Espinal , Trombose Venosa , Animais , Ratos , Heparina de Baixo Peso Molecular , Traumatismos da Medula Espinal/tratamento farmacológico , Anticoagulantes/farmacologia , Anticoagulantes/uso terapêutico , Administração Intravenosa , Hirudinas , Trombose Venosa/tratamento farmacológico , Trombose Venosa/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA